公开(公告)号：US09956194B2

公开(公告)日：2018-05-01

申请号：US14958610

申请日：2015-12-03

申请人： VELICEPT THERAPEUTICS, INC.

发明人： Eliot Ohlstein ,  Raymond E. Stevens, Jr. ,  H. Jeffrey Wilkins

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K9/20 ,  A61K9/24 ,  A61K45/06 ,  A61K9/16 ,  A61K9/50

CPC分类号： A61K31/196 ,  A61K9/0053 ,  A61K9/1676 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/5078 ,  A61K9/5084 ,  A61K45/06 ,  A61P31/10

摘要： This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

公开(公告)号：US20180099053A1

公开(公告)日：2018-04-12

申请号：US15496751

申请日：2017-04-25

申请人： Lipocine Inc.

发明人： David Fikstad ,  Srinivasan Venkateshwaran ,  Chandrashekar Giliyar ,  Mahesh Patel

IPC分类号： A61K47/44 ,  A61K31/225 ,  A61K31/35 ,  A61K9/16 ,  A61K9/48 ,  A61K47/14 ,  A61K31/403 ,  A61K9/20 ,  A61K47/10 ,  A61K31/355 ,  A61K31/17 ,  A61K31/366 ,  A61K31/34 ,  A61K47/22 ,  A61K31/568 ,  A61K31/28 ,  A61K31/401 ,  A61K47/40 ,  A61K31/265 ,  A61K31/66 ,  A61K47/12 ,  A61K31/404 ,  A61K31/4709 ,  A61K47/34 ,  A61K9/00 ,  A61K31/724 ,  A61K47/26

CPC分类号： A61K47/44 ,  A61K9/0004 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/4808 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/17 ,  A61K31/225 ,  A61K31/265 ,  A61K31/28 ,  A61K31/34 ,  A61K31/35 ,  A61K31/355 ,  A61K31/366 ,  A61K31/401 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4709 ,  A61K31/568 ,  A61K31/66 ,  A61K31/724 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/40

摘要： Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

公开(公告)号：US20180092868A1

公开(公告)日：2018-04-05

申请号：US15720947

申请日：2017-09-29

申请人： Biotie Therapies, Inc.

发明人： Christopher G. SALENTINE ,  Thomas R. MALEFYT

IPC分类号： A61K31/17 ,  A61K9/20

CPC分类号： A61K31/17 ,  A61K9/2054 ,  A61K9/2077

摘要： The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

公开(公告)号：US20180085316A1

公开(公告)日：2018-03-29

申请号：US15564576

申请日：2016-05-13

申请人： Insucaps Limited

发明人： Sinead Bleiel ,  Sam Maher

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K38/28

CPC分类号： A61K9/1658 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2072 ,  A61K9/2077 ,  A61K38/28

摘要： A gelated microparticle suitable for delivery intact to the mammalian lower intestine via an oral route comprises a monodispersed matrix formed of at least partially hydrolysed casein, chitosan, and an active agent, and includes a minor amount of at least one permeation enhancer dispersed throughout the matrix.

公开(公告)号：US20180055774A1

公开(公告)日：2018-03-01

申请号：US15801409

申请日：2017-11-02

申请人： ALKERMES PHARMA IRELAND LIMITED

发明人： Sean Cunningham ,  Seamus Mulligan ,  Michael Myers

IPC分类号： A61K9/20 ,  A61K47/44 ,  A61K47/38 ,  A61K47/14 ,  A61K31/4409 ,  A61K31/44 ,  A61K47/12

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

公开(公告)号：US09895325B2

公开(公告)日：2018-02-20

申请号：US14654317

申请日：2013-12-19

申请人： SYNTHON B.V.

发明人： Deepak Murpani ,  Marta Vivancos Martinez

IPC分类号： A61K31/137 ,  A61K9/20

CPC分类号： A61K31/137 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077

摘要： The present invention relates to a tablet composition comprising a therapeutically effective dose of cinacalcet hydrochloride having a particle size distribution D90 equal to or less than 30 μm in an amount of from 40% to 60% by weight based on the total weight of the composition, and one or more pharmaceutically acceptable excipients.

公开(公告)号：US20180042920A1

公开(公告)日：2018-02-15

申请号：US15499645

申请日：2017-04-27

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/14 ,  A61K31/4748 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US20170360734A1

公开(公告)日：2017-12-21

申请号：US15534372

申请日：2015-12-07

申请人： SYNAPTAMINE, INC.

发明人： Kenneth Blum

IPC分类号： A61K31/198 ,  A61K9/20 ,  A61K9/107 ,  A61K38/05 ,  A61K9/08

CPC分类号： A61K31/198 ,  A61K9/08 ,  A61K9/1075 ,  A61K9/127 ,  A61K9/2077 ,  A61K38/05

摘要： Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water.

公开(公告)号：US20170340632A1

公开(公告)日：2017-11-30

申请号：US15618055

申请日：2017-06-08

申请人： VeroScience LLC

发明人： Anthony H. Cincotta ,  Craig Michael Bowe ,  Paul Clark Stearns ,  Laura Jean Weston

IPC分类号： A61K31/4985 ,  A61K9/20 ,  A61K9/14 ,  A61K31/48

CPC分类号： A61K31/4985 ,  A61K9/14 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/48

摘要： The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

公开(公告)号：US09814708B2

公开(公告)日：2017-11-14

申请号：US15044655

申请日：2016-02-16

申请人： Auspex Pharmaceuticals, Inc.

发明人： Andreas Sommer ,  Chengzhi Zhang ,  John Carter ,  John Arthur ,  Margaret Bradbury ,  Thomas Gant ,  Manouchehr Shahbaz

IPC分类号： C07D455/06 ,  C07D471/04 ,  A61K31/4745 ,  A61K31/473 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50 ,  A61K45/06

CPC分类号： A61K31/473 ,  A61K9/0053 ,  A61K9/0065 ,  A61K9/1676 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/28 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/4745 ,  A61K45/06 ,  C07B2200/05 ,  C07D455/06

摘要： The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.